the method of delivery of the AAV virus however it has / is being used in various forms by Neurologix, Ceregene and Oxford Biomedica in existing gene therapy studies.

I believe in these other studies it is delivered via stereotactic injection in the brain, a procedure not without its risks as Carolyn can evidence. Still a small price to pay if the results are good.

No reason to assume the AMT study will not work in the same way.

AAV was reviewed last year by the FDA when a gene therapy trialist died (not a PD trial) however it was found to be safe and not connected to the death.

Neil.